| 5.53 -0.85 (-13.32%) | 10-09 15:27 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 8.98 | 1-year : | 11.09 |
| Resists | First : | 7.69 | Second : | 9.5 |
| Pivot price | 6.12  |
|||
| Supports | First : | 4.76 | Second : | 3.96 |
| MAs | MA(5) : | 6.36 |
MA(20) : | 5.81 |
| MA(100) : | 5.11 |
MA(250) : | 5.02 |
|
| MACD | MACD : | 0.3 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 30.8 |
D(3) : | 36.2 |
| RSI | RSI(14): 47.6 |
|||
| 52-week | High : | 29.28 | Low : | 1.62 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DWTX ] has closed above bottom band by 36.0%. Bollinger Bands are 299.3% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.92 - 6.96 | 6.96 - 6.99 |
| Low: | 6.21 - 6.25 | 6.25 - 6.28 |
| Close: | 6.32 - 6.39 | 6.39 - 6.45 |
Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia. It also develops IMC-2, a combination of valacyclovir and celecoxib for the treatment of managing the fatigue, sleep, attention, pain, autonomic function, and anxiety associated with long COVID. The company was formerly known as Virios Therapeutics, Inc. and changed its name to Dogwood Therapeutics, Inc. in October 2024. The company was founded in 2012 and is headquartered in Alpharetta, Georgia.
Wed, 01 Oct 2025
Dogwood Therapeutics files to sell 28.04M shares of common stock for holders - MSN
Tue, 30 Sep 2025
Dogwood Therapeutics stock price target raised to $12 from $10 at H.C. Wainwright - Investing.com
Tue, 30 Sep 2025
HC Wainwright & Co. Maintains Dogwood Therapeutics (DWTX) Buy Recommendation - Nasdaq
Tue, 30 Sep 2025
Dogwood Therapeutics (DWTX) Price Target Raised by HC Wainwright - GuruFocus
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 2 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 13 (%) |
| Held by Institutions | 5.9 (%) |
| Shares Short | 34 (K) |
| Shares Short P.Month | 47 (K) |
| EPS | -19.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | -9.48 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -22.7 % |
| Return on Equity (ttm) | -57.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -16 (M) |
| Levered Free Cash Flow | -10 (M) |
| PE Ratio | -0.3 |
| PEG Ratio | 0 |
| Price to Book value | -0.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -0.82 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|